Management healthcare consultancy opens new offices in New York and London
The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.
Putnam Associates, a US-based strategic management healthcare consultancy and part of UDG Healthcare, has recently opened two new offices in New York and London.
Headquartered in Boston with an office in San Francisco, Putnam employs more than 130 people and offers specialist consultancy services across the product life cycle to life science organisations with particular strengths in product commercialisation, market access strategy, and medical and scientific affairs.
The consultancy is opening new offices in Chiswick, London and in Midtown Manhattan, New York as part of its strategy to increase its global footprint and offer more localised support to its clients.
Putnam will also tap into the talent pools of both cities and plans to recruit experienced associates and management consultants across a number of roles in both locations.
Commenting on the new offices, Remco op den Kelder, CEO said: “Being part of UDG has created a number of opportunities for Putnam to leverage the infrastructure and resources of a global leader in life science services in a number of key regions.
“Our new office in London is a huge opportunity for us to access the European market.”
Putnam significantly strengthened the breadth of services offered by Ashfield’s Advisory division when it was acquired in early 2019. The consultancy added capabilities and scale to the existing advisory pillar, in particular in the global pricing, value and access area.
Op den Kelder continued: “Our new locations will also enable us to add to our talented teams as we look to recruit at every level, from senior leaders and experienced management consultants to graduates looking to start a career in the sector.
“The life sciences is an exciting industry to be a part of, the work we do is impactful and we work in a very dynamic environment so we’re always searching for top performers to join us.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance